Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001410939-21-000011
Filing Date
2021-04-07
Accepted
2021-04-07 16:06:27
Documents
12
Period of Report
2021-04-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A proxystatementfor2021annua.htm DEF 14A 984939
2 a03fs4c_ivericxbioxcommonxb.jpg GRAPHIC 347505
3 a03fs4c_ivericxbioxcommonxc.jpg GRAPHIC 983596
4 ab1a.jpg GRAPHIC 3901
5 ag1a.jpg GRAPHIC 3861
6 atriskpay1a.jpg GRAPHIC 53570
7 cr1a.jpg GRAPHIC 5417
8 gs1a.jpg GRAPHIC 5506
9 ivericlogo1a.jpg GRAPHIC 11159
10 jh1a.jpg GRAPHIC 4817
11 mb1a.jpg GRAPHIC 4137
12 realizablepay1a.jpg GRAPHIC 36809
  Complete submission text file 0001410939-21-000011.txt   2998467
Mailing Address 5 PENN PLAZA SUITE 2372 NEW YORK NY 10001
Business Address 5 PENN PLAZA SUITE 2372 NEW YORK NY 10001 212-845-8200
IVERIC bio, Inc. (Filer) CIK: 0001410939 (see all company filings)

EIN.: 208185347 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36080 | Film No.: 21812168
SIC: 2834 Pharmaceutical Preparations